VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration.

被引：0
|
作者：
Yamamoto, K. [1 ]
Kuwahara, M. [1 ]
Yamamoto, S. [1 ]
机构：
[1] Int Univ Hlth & Welf, Med Kouhoukai Takagi Hosp, Thorac Surg, Ohkawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
VATS right upper lobectomy; ALK-tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.20
引用
收藏
页码：S666 / S667
页数：2
相关论文
共 50 条
  • [11] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
    Topibulpong, N.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Sriuranpong, V
    VALUE IN HEALTH, 2010, 13 (07) : A512 - A513
  • [13] 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
    Tanaka, Y.
    Umemura, S.
    Sugiyama, E.
    Sakai, T.
    Izumi, H.
    Zenke, Y.
    Matsumoto, S.
    Yoh, K.
    Goto, K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [14] Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer
    Cryer, Alexander M.
    Chan, Cheuk
    Eftychidou, Anastasia
    Maksoudian, Christy
    Mahesh, Mohan
    Tetley, Teresa D.
    Spivey, Alan C.
    Thorley, Andrew J.
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (18) : 16336 - 16346
  • [15] EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer
    Kowalski, D. M.
    Krzakowski, M.
    Jaskiewicz, P.
    Janowicz-Zebrowska, A.
    Glogowski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [16] Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?
    Nguk Chai Diong
    Chia-Chuan Liu
    Chih-Shiun Shih
    Mau-Ching Wu
    Chun-Jen Huang
    Chen-Fang Hung
    World Journal of Surgical Oncology, 20
  • [17] Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?
    Diong, Nguk Chai
    Liu, Chia-Chuan
    Shih, Chih-Shiun
    Wu, Mau-Ching
    Huang, Chun-Jen
    Hung, Chen-Fang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [18] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [19] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [20] Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1173 - S1176
12345